Emergent BioSolutions Inc (EBS) Stock AnalysisEBSEmergent BioSolutions Inc

Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Emergent BioSolutions Inc is not a good buy right now due to significant financial losses and bearish market sentiment. The current price is $6.38, and the company reported a staggering net loss of $180.2 million in Q2 2026, which has led to a year-to-date decline of 49%. Furthermore, insider selling has increased by 140.86%, indicating a lack of confidence from those closest to the company.

6 analysts cover EBS: 5 rate it Buy, 1 Hold and 0 Sell. The average price target is 15.00.